University of california - Articles - Page 2

Neurology/psychiatric

University of California discovers new 5-HT2 and muscarinic receptor ligands

Feb. 4, 2025

University of California has described tropane derivatives acting as 5-HT2 and muscarinic receptor ligands reported to be useful for the treatment of psychiatric disorders, depression, neurodegeneration, substance abuse and dependence, migraine, Alzheimer’s disease and Parkinson’s disease.

Cancer

University of California patents KRAS inhibitors

Jan. 29, 2025

A University of California patent describes new inhibitors of GTPase KRAS, particularly KRAS G12D mutant, reported to be useful for the treatment of cancer.

Neurology/psychiatric

US scientists patent ER-β ligands for endometriosis and multiple sclerosis

Oct. 3, 2024

Scientists at University of California and University of Illinois have disclosed compounds acting as estrogen receptor β (ER-β; ESR2) ligands.

Patents

UCLA researchers file patent for cardiopulmonary support cannula

Sep. 23, 2024

By Simon Kerton

Researchers from UCLA’s Department of Cardiac Surgery filed for protection of a smart multistage peripherally inserted cannula with active fixation for temporary cardiopulmonary support which simultaneously drains both sides of the heart.

Neurology/psychiatric

ECTRIMS 2024: Time for neuroprotection

Sep. 19, 2024

By Coia Dulsat

The Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Copenhagen this week is celebrating its 40th edition. In recognition of this landmark, the plenary session and opening lecture were attended by Queen Margrethe of Denmark. Afterward, the hot topic session on neuroprotective therapies set the stage for the subsequent discussions on the latest trends in the management and treatment of multiple sclerosis (MS).

Cancer

University of California, US VA report new AR antagonists

Sep. 10, 2024

The University of California and the US Department of Veterans Affairs have patented androgen receptor (AR) antagonists reported to be useful for the treatment of prostate cancer.

Cancer

Sun Pharmaceutical Advanced Research and the University of California present new ligand-drug conjugates

Aug. 9, 2024

Researchers from Sun Pharmaceutical Advanced Research Co. Ltd. and the University of California have synthesized drug conjugates consisting of PSMA targeting moiety covalently linked to therapeutic and/or cytotoxic agent reported to be useful for the treatment of cancer.

Neurology/Psychiatric

University of California Oakland discovers new activators of KCNK2 and KCNK10

April 16, 2024

University of California Oakland has described potassium channel subfamily K member 2 (TREK-1; KCNK2) and/or potassium channel subfamily K member 10 (TREK2; KCNK10) activators reported to be useful for the treatment of Caisson disease (decompression sickness), depression, headache, pulmonary hypertension, insomnia, chronic pain, lung and neuronal Injury.

Cancer

University of California Oakland presents new GTPase KRAS mutant inhibitors

March 21, 2024

University of California Oakland has divulged GTPase KRAS (G12R mutant) inhibitors reported to be useful for the treatment of cancer.

Patent: “Methods and systems for detecting stroke.”

Point-of-care brain monitoring algorithm for detecting stroke in children

March 14, 2024

By Simon Kerton

In what represents their first patenting, a researcher from the University of California is seeking protection for non-invasive methods of brain monitoring that use electroencephalography (EEG) to detect new or worsening brain injury in pediatric patients.